CARsgen® Announces 2024 Interim Results
SHANGHAI, Aug. 29, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, has announced its 2024 Interim Results. Business Highlights Zevor-cel was approved by NMPA in China. Patient enrollment for the confirmatory Phase II...
Viva Biotech Announces Its 2024 Interim Results: Significant Improvement in Net Profit Growth and Ongoing Optimization of Emerging Technology Platforms
Results Highlights for Interim Results ended 30 June 2024 Revenue reached RMB981.8 millionGross profit amounted to RMB339.1 millionNet profit grew by 956.0 YoY to RMB144.2 millionAdjusted non-IFRS net profit reached RMB168.2 million, increased by 15.1% YoY HONG KONG, Aug. 29, 2024 /PRNewswire/ -- On August 29, 2024, Viva Biotech Holdings Group ("Viva Biotech", "the Group" or "the Company", stock...
Medicilon Expands Global Presence with Official Opening of Second R&D Center in Massachusetts
BOSTON, Aug. 29, 2024 /PRNewswire/ -- In August 2024, Medicilon USA Corp (Medicilon) officially commenced operations at its second R&D center in Massachusetts, USA. Research at the new facility will focus on animal models for PK/PD and toxicology studies. This milestone heralds Medicilon's continued global business expansion. Medicilon's Second R&D Center in Massachusetts The Lexington, MA location was chosen...
UTime Initiates Financial and Legal Due Diligence on Bowen Therapeutics
SHENZHEN, China, Aug. 29, 2024 /PRNewswire/ -- UTime Limited (NASDAQ: WTO) ("UTime" or the "Company"), which continues to build on its strengths in the global healthcare sector, has announced that it has commenced a comprehensive financial and legal due diligence on Bowen Therapeutics Inc ("Bowen Therapeutics"), which it intends to acquire. The move marks an important step in UTime's expansion...
ZEISS innovation paves way to more personalized patient care with cutting-edge AI technology and industry-leading surgical solutions
Showcasing at ESCRS from Sept. 6 to 10, in Barcelona, Spain: REFRACTIVE INDUSTRY MILESTONES: ZEISS extends its global refractive industry momentum with more than 10 million eyes treated with ZEISS SMILE and ZEISS SMILE pro; ZEISS announces first treatment in the CE market for hyperopia with lenticule extraction using ZEISS SMILE pro technology....
So-Young Announces Receipt of Minimum Bid Price Notice from Nasdaq
BEIJING, Aug. 29, 2024 /PRNewswire/ -- So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company"), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced it has received a notification letter dated August 28, 2024 (the "Notice") from the staff of the Listing Qualifications Department of The...
Discover the Top 6 Highlights of Medtec 2024 and Explore the Latest Industry Trends
SHANGHAI, Aug. 29, 2024 /PRNewswire/ -- The 18th International Medical Device Design and Manufacturing Technology Exhibition (Medtec 2024) will be held at the Shanghai World Expo Exhibition and Convention Center from September 25th to 27th. This year's event will cover 42,000+㎡and feature over 1,000 companies from nearly 20 countries and regions, including the Netherlands, Germany, the U.S., and Japan....
Transcenta Holding Limited (Stock Code: 6628.HK) Announce 2024 Interim Results
2024 Interim Result Highlights (For the six months ended June 30, 2024) Company published the efficacy and safety data of Cohort-G of TranStar102 study for osemitamab (TST001), plus checkpoint inhibitor and CAPOX as the first-line treatment of patients with locally advanced or metastatic G/GEJ cancer at ASCO annual meeting, showing that high/medium Claudin18.2 expression is associated with a...
111, Inc. Announces Second Quarter 2024 Unaudited Financial Results
Maintained Operational Profitability for the Second Consecutive Quarter Operating Expenses as a Percentage of Revenues Decreased 120 Basis Points YoY Held Positive Operating Cash Flow for Two Consecutive Quarters SHANGHAI, Aug. 29, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry...
Biocon Biologics Secures Market Entry for Bmab 1200, a Proposed Biosimilar to Stelara®, in Europe, UK, Canada, and Japan
BENGALURU, India, Aug. 29, 2024 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today that the Company has signed a settlement and license agreement with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson (collectively known...
